1. Home
  2. revoinews
  3. COVID-19: Zydus starts human dosing of its vaccine ‘ZyCoV-D’
COVID-19: Zydus starts human dosing of its vaccine ‘ZyCoV-D’

COVID-19: Zydus starts human dosing of its vaccine ‘ZyCoV-D’

  • Begins Adaptive Phase I/ II human clinical trials of its plasmid DNA vaccine, ZyCoV-D
  • ZyCoV-D found safe, immunogenic, well-tolerated in the pre-clinical toxicity studies.
  • The vaccine elicited high level of neutralizing antibodies in animal studies.

Ahmedabad: Zydus, an innovation-driven global healthcare company, on Wednesday, announced that the Adaptive Phase I/ II human clinical trials of its plasmid DNA vaccine, ZyCoV-D has commenced with the first human dosing.

The Adaptive Phase I/II dose-escalation, the multi-centric study will assess the safety, tolerability, and immunogenicity of the vaccine. The human dosing of the vaccine marks a key milestone since the launching of the accelerated vaccine development program for COVID-19 in February 2020, said Pankaj R. Patel, Chairman of the Ahmedabad-based company.

“This is an all-important step in our fight against COVID-19. We acknowledge the support of the National Biopharma Mission, BIRAC, Department of Biotechnology, Govt. of India, and regulatory agencies ICMR and DGCI in the development of the ZyCoV-D vaccine candidate.  We look forward to the Adaptive Phase I/I I clinical studies and gathering important data on ZyCoV-D in the months ahead.”     

In the Adaptive Phase I/ II clinical trials, Zydus will be enrolling over 1,000 subjects across multiple clinical study sites in India. The company has already manufactured clinical GMP batches of the vaccine candidate for the clinical trials.

Zydus had earlier this month announced that its plasmid DNA vaccine candidate (ZyCoV-D) developed at its Vaccine Technology Centre in Ahmedabad, had successfully completed the preclinical phase and received permission from the Drug Controller General of India – Central Drugs Standard Control Organisation (CDSCO) to initiate Adaptive Phase I/II human clinical trials in India.

About ZyCoV-D

In the pre-clinical phase, the vaccine was found to elicit a strong immune response in multiple animal species like mice, rats, guinea pigs and rabbits. The antibodies produced by the vaccine were able to neutralize the wild type virus in virus neutralization assay indicating the protective potential of the vaccine candidate. No safety concerns were observed for the vaccine candidate in repeat dose toxicology studies by both intramuscular and intradermal routes of administration. In rabbits, up to three times the intended human dose was found to be safe, well tolerated and immunogenic.

With ZyCoV-D, the company has successfully established the DNA vaccine platform in the country using non-replicating and non-integrating plasmid carrying the gene of interest making it safe. Further, no vector response and with absence of any infectious agent, the platform provides ease of manufacturing the vaccine with minimal biosafety requirements (BSL-1).

The platform is also known to show much-improved vaccine stability and lower cold chain requirements making it easy for transportation to remotest regions of the country. Also, the platform can be rapidly used to modify the vaccine in a couple of weeks in case the virus mutates to ensure that the vaccine still elicits protection.



Your email address will not be published.